anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Plaque stability is an important criterion for selecting different treatment strategies (interventional and antithrombotic). High-risk plaque characteristics are also considered to be related to the overall incidence of Major Adverse Cardiovascular Events (MACE). Single-modality intravascular imaging has inherent disadvantages in identifying atherosclerotic plaques, while the combination of IVUS, OCT, and NIRS enables multimodal intravascular imaging techniques to complement each other in obtaining plaque information. There is currently a lack of research on the prognostic benefits of multimodal intravascular imaging in assessing atherosclerotic plaques. This study is a multicenter, prospective, observational clinical study that will be conducted at 11 hospitals, enrolling approximately 500 subjects. It will use intravascular ultrasound (IVUS) and optical coherence tomography-near-infrared spectroscopy (OCT) to assess the morphology and stability of non-culprit lesions in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI), and will follow up at 1 month, 1 year, 2 years, and 5 years post-surgery. The aim is to compare the clinical outcomes between high-risk and non-high-risk patients, as well as between high-risk and non-high-risk plaques defined by multimodal intravascular imaging, and to explore the predictive value of high-risk plaque characteristics shown by multimodal intravascular imaging for adverse cardiovascular events in patients with ACS.
The goal of this study is to develop and evaluate advanced annular-array transducer technology for rapid, high-definition imaging. The study will assess high frequency ultrasound (HFU, 40 \& 20 MegaHertz) annular arrays in imaging posterior vitreous detachments (PVDs) associated with diabetic retinopathy, the leading cause of blindness in the US working-age population according to Prevent Blindness America. Current HFU instruments do not use linear arrays for such applications because of a variety of technical and cost reasons. Instead, current HFU instruments use mechanically scanned, single-element transducers, which provide fine-resolution images over a very limited depth of field (DOF). For ophthalmic applications, a shallow DOF causes most ocular anatomy to be imaged with poor definition compared to the in-focus region; therefore, because only a small portion of the eye is in focus at a given time, detection and assessment of ocular conditions such as PVD are prone to inaccuracies and false-negative determinations. Annular-array transducers offer a promising approach to significantly extend DOF and to increase the depth range over which fine-lateral resolution is provided. The investigators will validate system performance using animal experiments and human-subject examinations. First, in vivo animal experiments will be conducted to evaluate a 40-MegaHertz (MHz) annular array for anterior-segment imaging and a 20-MHz annular array for posterior segment and full-globe imaging. The investigators will test the hypothesis that 20-MHz annular arrays improve detection of PVD. Validation of this hypothesis will significantly improve our ability to assess disease status in diabetic retinopathy.
The invention discloses a method for automatically creating a clinical test project file, which comprises the following steps: a first template is determined based on the raw data. And based on the first template, collecting related second templates from other clinical test project files, and combining the second templates into a comprehensive template set. And filling the original data into the comprehensive template set to generate a draft of the project file. And (5) manually checking the draft to generate a final clinical test project file. The invention creatively discloses a method for automatically creating a clinical test project file, solves the problem of integrating new project input with existing clinical test data, balances team angular color difference and confidentiality requirements, and directly improves the design and execution quality of clinical tests. Comprising the following steps: data omission is prevented, and expansion of a template frame is realized: ensuring the sufficiency and accuracy of research; data confidentiality enhancement: strict data access control is implemented to ensure the security of sensitive information.
PURPOSE: Very little is known about the subjective well-being (SWB) of adults with a congenital corpus callosum disorder (CCD), the extent to which they feel satisfied with their lives, and what might be helpful in improving their SWB and quality of life. This study measured SWB among Australian adults with a CCD and compared the results with normative data for the wider Australian adult population.
METHODS: Online surveys were completed independently by 53 Australian adults with a CCD. Data included demographic profiles and answers to questions about satisfaction with life, employing the Personal Wellbeing Index (PWI) and one open ended question. Domains measured included life as a whole, standard of living, health, achieving in life, personal relationships, safety, community connectedness and future security. The PWI results were statistically analysed and means compared with Australian normative data. The qualitative data were analysed using deductive thematic analysis.
RESULTS: Australian adults with a CCD responded with ratings significantly below what might be expected of the adult Australian population in all domains except for standard of living and safety. Quantitative analysis results were supported by qualitative thematic analysis, expressing particular challenges and barriers to feeling satisfaction with life as a whole, personal relationships, achieving in life, health and future security.
CONCLUSION: Evidence from the PWI and accompanying qualitative responses indicate that SWB of Australian adults with CCD is significantly reduced compared with the general population. Further research is needed to examine the lived experience and explore solutions for support of this community.
Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
PURPOSE:To provide a dental material having improved hardness, tensile strength, flexural strength, etc., and extremely excellent processability and handleability, by compounding a small amount of silicon nitride whisker to a plastic dental material. CONSTITUTION:A resin for artificial tooth, denture base, artificial crown or restorative dental material, is compounded with <= 20wt%, preferably 3-5wt% of silicon nitride whisker (preferably having a diameter of about 0.5mu and a length of about 100mu). For example, in the case of a resin for denture base (e.g. methacrylate polymer, polysulfone resin, etc.), the thickness can be decreased from the standard 1.3-1.4mm. to 0.7mm. without causing breakage and keeping high hardness and strength. The uncomfortable and disagreeable feeling to the palate can be decreased remarkably, and at the same time, a sufficiently high chewing capability can be attained.
During the wound healing process, the activation of signal transducer and activator of transcription 3 (STAT3) is considered crucial for the migration and proliferation of epithelial cells, as well as for establishing the inflammatory environment. However, an excessive STAT3 activation aggravates scar formation. Here we show that 450 nm blue light and 630 nm red light can differentially regulate the phosphorylation of STAT3 (p-STAT3) and its downstream cytokines in keratinocytes. Further mechanistic studies reveal that red light promotes wound healing by activating the PI3 kinase p110 beta (PI3Kβ)/STAT3 signaling axis, while blue light inhibits p-STAT3 at the wound site by modulating cytochrome c-P450 (CYT-P450) activity and reactive oxygen species (ROS) generation. In a mouse scar model, skin wound healing can be significantly accelerated with red light followed by blue light to reduce scar formation. In summary, our study presents a potential strategy for regulating epithelial cell p-STAT3 through visible light to address skin scarring issues and elucidates the underlying mechanisms.
The invention relates to a medicine for treating the acute renal failure. The medicine is prepared from, by weight, 10 parts of rhubarb, 6 parts of gleditsia sinensis sting, 9 parts of Lepidium apetalum Willd., 9 parts of Ajuga forrestii Diels, 10 parts of Onychium contigum(Wall.)Hope, 6 parts of alpine clintonia, 9 parts of Orixa japonica Thunb., 6 parts of Cirsium pendulum Fisch.ex DC., 20 parts of coix seeds, 12 parts of Lissorhoptrus oryzophilus Kus and 6 parts of radix glycyrrhizae. The medicine has the advantages that rhubarb purges heat and relieves intestines, cools blood and removes toxin, and removes stasis and stimulates menstrual flow; gleditsia sinensis sting can stimulate meridian, promote qi and blood, and remove stasis; Lepidium apetalum Willd., Ajuga forrestii Diels and Onychium contigum(Wall.)Hope clear away heat and toxic materials, and induce diuresis for treating stranguria; alpine clintonia dispels wind and removes toxin, and removes stasis; Orixa japonica Thunb. clears away heat and promotes diuresis, and soothes nerves; Cirsium pendulum Fisch.ex DC. removes toxin and tonifying deficiency; coix seeds strengthen spleen and excrete dampness, remove numbness and stop diarrhea, and clear away heat and remove pus; Lissorhoptrus oryzophilus Kus relieves exterior syndromes and dispels cold, stimulates meridian, and induces urination; radix glycyrrhizae strengthens spleen and nourishes qi, clears away heat and toxic materials, expels phlegm to arrest coughing, relieves emergency and stops pain, and coordinates medicine actions; the medicine components are used in cooperation and play a role in clearing away heat and toxic materials, promoting blood circulation to remove stasis, and removing qi obstruction for diuresis; it is proved through clinical experiments that the medicine can safely and effectively treat the acute renal failure.
Systems, media and methods for staggered medical transactions are provided. A method includes displaying a plurality of products on a display client. The method may further include receiving, at the display client, input from a user selecting a product. The method may also further include prompting the user via the display client to continue on another device. The method may additionally include outputting, via the display client, an identifier associated with the product and the user. The method may also additionally include receiving the identifier at a user device after the user has been authenticated at the user device. The method may still further include receiving confirmation input at the user device from the user confirming selection of the product. The method may also still further include outputting, from the user device, the confirmation data based upon the confirmation input.
The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin. Accordingly, the present invention relates to a method of treating hyperglycemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of Gfi1.
PURPOSE:To prepare a liquid Chinese MISO (fermented bean paste) acceptable even by Japanese, by using herb medicines, tangle root, nonglutinous rice, etc., as raw material, and subjecting the raw material to a specific treatment. CONSTITUTION:Almost equal amounts of JIO (root of Rehmannia glutinosa), BUKURYO (fungus of Pachyma hoelen), TOKI (root of Angelica acutiloba), BYAKUJUTSU (rhizome of Atractylodes lancea), SENKYU (rhizome of Cnidium officinale), SHAKUYAKU (root of Paeonia albiflora), KEIHI (bark of Cinnamomum cassia), NINJIN (rhizome of Panax ginseng), OUGI (root of Astragalus huantchy) and KANZO (root of Glycyrrhiza glabra) are put into a juice bag together with tangle root of an amount nearly equal to the sum of the above herb medicines. The bag is immersed in boiling water for 30min to extract the herb medicines. Washed nonglutinous rice is added to the filtrate of the above extracted liquid and boiled for 30min. The product is added with soybean flour and powder of YOKUI (Coix lacryma-jobi; a herb medicine), heated under stirring and boiled for 1hr. The boiled extract is mixed with salt and forcibly cooled. When the temperature is lowered to 35 deg.C, the liquid is mixed with malt and fermented in a fermentation tank at 30-38 deg.C for 90 days. Finally, the product is mixed with water to adjust the salt concentration, sterilized and filled in a desired container.
PROBLEM TO BE SOLVED: To provide a medical accounting system that can reduce the burden imposed on a medical account operator by simplifying operation and prevent a superfluous demand for payment, an omission in the demand for payment, or the like as medical account. SOLUTION: A medical account delivery software (a medical reminder) is installed in a doctor terminal 5. In the case of carrying out instructions to a specific disease patient, medical treatment action information is recorded in an electronic medical card device 1 using the medical reminder. The medical treatment action information is further transmitted to a medical accounting device 2 from the electronic medical card device 1. That is, in the medical reminder, instruction fee operation information and medical account transmission instruction fee information are registered in connection with each other, and a corresponding item is selected from the instruction fee operation information displayed over the electronic medical and display part of the medical reminder.  Date information is added to the selected item to acquire the medical account transmission instruction fee information which is transmitted to the medical accounting device 2 from the electronic medical card device.
Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute \[ATA\]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an "air break." They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours.
Anaplastic large cell lymphoma (ALCL) is an aggressive, CD30+ T cell lymphoma of children and adults. ALK fusion transcripts or mutations in the JAK-STAT pathway are observed in most ALCL tumors, but the mechanisms underlying tumorigenesis are not fully understood. Here, we show that dysregulated STAT3 in ALCL cooccupies enhancers with master transcription factors BATF3, IRF4, and IKZF1 to form a core regulatory circuit that establishes and maintains the malignant cell state in ALCL. Critical downstream targets of this network in ALCL cells include the protooncogene MYC, which requires active STAT3 to facilitate high levels of MYC transcription. The core autoregulatory transcriptional circuitry activity is reinforced by MYC binding to the enhancer regions associated with STAT3 and each of the core regulatory transcription factors. Thus, activation of STAT3 provides the crucial link between aberrant tyrosine kinase signaling and the core transcriptional machinery that drives tumorigenesis and creates therapeutic vulnerabilities in ALCL.
Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase \& continued for the remaining year during the HL phase for about a year.
PROBLEM TO BE SOLVED: To potentiate immunity by adding an extract of Cistanche salsa to an immune system so as to enhance antibody production, to promote class switch and to enhance interleukin-6 production. SOLUTION: Dried Cistanche salsa (preferably stem or root) is ground into ground material or powder, extracted with water or an alcohol solution (e.g. 80% methyl alcohol) at 60 deg.C for 20-120 minutes or 80 deg.C for 10-60 minutes and filtered to give an extract of Cistanche salsa. The prepared extract is used as it is or may be concentrated or dried. Since the active substance contained in the extract of Cistanche salsa is stable in heat treatment at 60 deg.C for 30 minutes but deactivated by heat treatment at 100 deg.C for 10 minutes, the treatment temperature and time need attention. When the extract of Cistanche salsa is added to an immune system, an antibody as the center of in vivo defense mechanism can be produced in a large amount in an early stage to activate the immune system.
Bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
Bortezomib for injection, a proteasome inhibitor, contains bortezomib which is an antineoplastic agent. Bortezomib is a modified dipeptidyl boronic acid. The chemical name for bortezomib, the monomeric boronic acid, is [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid. 

Bortezomib has the following chemical structure: 

The molecular weight is 384.24. The molecular formula is C19H25BN4O4. The solubility of bortezomib, as the monomeric boronic acid, in water is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5. 

Bortezomib for injection is available for intravenous injection or subcutaneous use. Each single-dose vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. It also contains the inactive ingredient: 35 mg mannitol, USP. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine.
BACKGROUND AND OBJECTIVE: Immunosuppressive therapy (IST) is the first choice for severe aplastic anemia (SAA) patients with hematopoietic stem cell transplantation (HSCT) limitation, and the main factor limiting its efficacy is too few residual hematopoietic stem/progenitor cells (HSPC). Eltrombopag (EPAG), as a small molecule thrombopoietin receptor agonist, can stimulate the proliferation of residual HSPC and restore the bone marrow hematopoietic function of patients. In recent years, many studies have observed the efficacy and safety of IST combined with EPAG in the treatment of SAA, but the results are still controversial. The aim of this study is to systematically evaluate the efficacy and safety of IST combined with or without EPGA in the treatment of SAA.
METHODS: We conducted a systematic review of all relevant literature published up to January 19, 2024. Pooled odds ratio (OR) was calculated to compare the rates, along with 95% confidence intervals (CI) and p value to assess whether the results were statistically significant by Review Manager 5.4.1. The p values for the interactions between each subgroup were calculated by Stata 15.1. The Newcastle-Ottawa Scale and the Cochrane bias risk assessment tools were respectively used to evaluate the quality of the literature with cohort studies and randomized controlled trials. The Review Manager 5.4.1 and Stata 15.1 were used to assess bias risk and perform the meta-analysis.
RESULTS: A total of 16 studies involving 2148 patients were included. The IST combined with the EPAG group had higher overall response rate (ORR) than the IST group at 3 months (pooled OR = 2.10, 95% CI 1.58-2.79, p < 0.00001) and 6 months (pooled OR = 2.13, 95% CI 1.60-2.83, p < 0.00001), but the difference between the two groups became statistically insignificant at 12 months (pooled OR = 1.13, 95% CI 0.75-1.72, p = 0.55). The results of complete response rate (CRR) (pooled OR at 3 months = 2.73, 95% CI 1.83-4.09, p < 0.00001, 6 months = 2.76, 95% CI 2.08-3.67, p < 0.00001 and 12 months = 1.38, 95% CI 0.85-2.23, p = 0.19) were similar to ORR. Compared with the IST group, the IST combined with the EPAG group had better overall survival rate (OSR) (pooled OR = 1.70, 95% CI 1.15-2.51, p = 0.008), but there were no statistically significant differences in event-free survival rate (EFSR) (pooled OR = 1.40, 95% CI 0.93-2.13, p = 0.11), clonal evolution rate (pooled OR = 0.68, 95% CI 0.46-1.00, p = 0.05) and other adverse events between the two groups. The results of subgroup analysis showed that different ages were a source of heterogeneity, but different study types and different follow-up times were not. Moreover, all p-values for the interactions were greater than 0.05, suggesting that the treatment effect was not influenced by subgroup characteristics.
CONCLUSION: EPAG added to IST enables patients to achieve earlier and faster hematologic responses with a higher rate of complete response. Although it had no effect on overall EFSR, it improved OSR and did not increase the incidence of clonal evolution and other adverse events.
The patient will be monitored with routine monitoring and ANI under operating room conditions. VAS values and vital signs before and after peripheral nerve block will be recorded. Patients will be placed in the lateral position and an erector spinae plane block will be applied under USG guidance by an experienced anesthesiologist. Surgery will be allowed 30 minutes after the block is performed.
Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition(High-fat meal) on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition （Low-fat meal）on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.